Long-acting cabotegravir and rilpivirine dosed every 2 months in adults with HIV-1 infection (ATLAS-2M), 48-week results: a randomised, multicentre, open-label, phase 3b, non-inferiority study-Reference-Cited by-同舟云学术

Long-acting cabotegravir and rilpivirine dosed every 2 months in adults with HIV-1 infection (ATLAS-2M), 48-week results: a randomised, multicentre, open-label, phase 3b, non-inferiority study

Published:2020-12 Issue:10267 Volume:396 Page:1994-2005
ISSN:0140-6736
Container-title:The Lancet
language:en
Short-container-title:The Lancet

Author:

Overton Edgar T,Richmond Gary,Rizzardini Giuliano,Jaeger Hans,Orrell Catherine,Nagimova Firaya,Bredeek Fritz,García Deltoro Miguel,Swindells Susan,Andrade-Villanueva Jaime Federico,Wong Alexander,Khuong-Josses Marie-Aude,Van Solingen-Ristea Rodica,van Eygen Veerle,Crauwels Herta,Ford Susan,Talarico Christine,Benn Paul,Wang Yuanyuan,Hudson Krischan J,Chounta Vasiliki,Cutrell Amy,Patel Parul,Shaefer Mark,Margolis David A,Smith Kimberly Y,Vanveggel Simon,Spreen William

Funder

ViiV Healthcare

Gilead Sciences

Janssen Pharmaceuticals

Merck

Publisher

Elsevier BV

Subject

General Medicine

Reference19 articles.

1. Efficacy of initial antiretroviral therapy for HIV-1 infection in adults: a systematic review and meta-analysis of 114 studies with up to 144 weeks' follow-up;Lee;PLoS One,2014

2. Patient-reported barriers to adherence to antiretroviral therapy: a systematic review and meta-analysis;Shubber;PLoS Med,2016

3. A systematic review of treatment fatigue among HIV-infected patients prescribed antiretroviral therapy;Claborn;Psychol Health Med,2015

4. Experiences and emotional challenges of antiretroviral treatment (ART)—findings from the Positive Perspectives Study;De Los Rios;Open Forum Infect Dis,2019

5. Acceptability and preferences for long-acting antiretroviral formulations among people with HIV infection;Dandachi;AIDS Care,2020

Cited by 160 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Comparison of HIV-1 DNA load measurements in blood and in relation to successful proviral sequencing;Infectious Diseases Now;2024-03

2. People with HIV pioneers of injectable cabotegravir and rilpivirine long acting in Italy: who are they?;AIDS;2024-02-01

3. Favorable Virological Outcome, Characteristics of Injection Site Reactions, Decrease in Renal Function Biomarkers in Asian People with HIV Receiving Long-Acting Cabotegravir Plus Rilpivirine;AIDS Research and Human Retroviruses;2024-02-01

4. Polymer Delivery Systems for Long-Acting Antiretroviral Drugs;Pharmaceutics;2024-01-28

5. Pharmacokinetics and tolerability of cabotegravir and rilpivirine long-acting intramuscular injections to the vastus lateralis (lateral thigh) muscles of healthy adult participants;Antimicrobial Agents and Chemotherapy;2024-01-10